USA flag logo/image

An Official Website of the United States Government

In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2010 / STTR
Agency Tracking Number:
R41RR028190
Solicitation Year:
2010
Solicitation Topic Code:
NCRR
Solicitation Number:
PA09-081
Small Business Information
YECURIS CORPORATION
3181 SW SAM JACKSON PARK RD, L321 PORTLAND, OR 97239-3098
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice
Agency: HHS
Contract: 1R41RR028190-01
Award Amount: $325,496.00
 

Abstract:

DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules exists. Our company (Yecuris Inc.) has developed an in vivo genetic selection system (the FRG mouse) that permits extensive humanization of murine liver by transplanted human hepatocytes. Preliminary data show that highly humanized mice (gt80%) accurately reflect most aspects of human drug metabolism. Therefore highly humanized FRG mice are an attractive novel system for modeling human drug metabolism and pharmacokinetics at an early stage of drug development. However, the extent of liver humanization achieved in our mice currently remains highly variable, ranging from lt 5% to gt90%. In order to make our platform more attractive to commercial customers and more commercially viable (reduced production cost per mouse), it will be necessary to reproducibly achieve high humanization levels in the majority of mice. In this phase 1 STTR application we propose 2 specific aims to advance our goal of reliable liver humanization: 1) We will test different background strains of mice for their ability to support high level liver repopulation. 2) The effects of different regimens to deplete/inhibit hepatic Kupffer cells on repopulation levels will be ascertained. PUBLIC HEALTH RELEVANCE: The animal model is an attractive novel system for modeling human drug metabolism and pharmacokinetics at an early stage of drug development. Commercialization of our technology will greatlyreduce the cost of and accelerate new drug development, thus contributing to public health.

Principal Investigator:

Markus Grompe
503-494-6888
grompem@ohsu.edu

Business Contact:

Hongxiang Lan
503-494-6889
lanh@ohsu.edu
Small Business Information at Submission:

YECURIS CORPORATION
3181 SW SAM JACKSON PARK RD, L321 PORTLAND, OR 97239-3098

EIN/Tax ID: 120895423
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Oregon Health And Science University
3181 SW Sam Jackson Pk Rd
PORTLAND, OR 97239-3098
Contact: